Switzerland· 55045001
Insulin NovoNordisk NovoRapid, Injektionslösung
A insulin aspart product, registered in Switzerland by Novo Nordisk Pharma AG and dispensed under Swissmedic category B. The same ATC class is registered in 11 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Insulin aspart is registered in 11 of 19 countries.
Countries holding a registration under ATC A10AB05 (insulin aspart), each read from that country’s own register.
- This record: Switzerland
- 7 of them publish a price we can compare per daily dose
Insulin aspart · ATC A10AB05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
- Manufacturer
- Novo Nordisk Pharma AG
- Country
- Switzerland (CH)
- ATC code
- A10AB05
- ATC class
- Insulin aspart
- Defined daily dose
- 40 E, P
- Swissmedic category
- B
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
434 interactions on record for insulin aspart.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Insulin aspart · interactions on record
434 records
- 15 severe
- 368 moderate
- 50 minor
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- PrednisoloneA07EA01moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A10AB05
Insulin aspart, as other registers publish it.
- DenmarkDazpardaGan & Lee Pharmaceuticals Europe GmbH
- FinlandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- PolandDazpardaGan & Lee Pharmaceuticals Europe GmbH
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- CzechiaDAZPARDAGan & Lee Pharmaceuticals Europe GmbH, Düsseldorf
- NetherlandsDazparda 100 eenheden/ml oplossing voor injectie in een voorgevulde penGan & Lee Pharmaceuticals Europe GmbH
- BelgiumDazparda 100 U/mlGan & Lee Pharmaceuticals Europe
- IrelandDazparda 100 units/ml solution for injection in pre-filled penGan & Lee Pharmaceuticals Europe GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c9ae81b1-6a03-4e62-b43f-7e866470f87c GET /v1/drugs/c9ae81b1-6a03-4e62-b43f-7e866470f87c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about insulin aspart.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.